HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$9.95
-0.05 (-0.50%)
▼
5d:
+2.58%
30d:
-8.46%
90d:
-1.39%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
28d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.81
Based on 7.1% avg growth
INTRINSIC VALUE TODAY
$9.82
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $9.95, which is considered slightly low relative to its 30-day fair value range of $9.90 to $10.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.4) compared to its historical average (18.4). Remarkably, the market is currently pricing in an annual earnings decline of 3.8% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. Immediate support is located at $9.64, while resistance sits at $10.46.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.09 (+20.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HLN is in a strong downtrend. Immediate support is located at $9.64, while resistance sits at $10.46.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.09 (+20.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$9.90 -
$10.77
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.9% below Wall St target ($12.09)
Fair Price Analysis
30-Day Fair Range
$9.90 -
$10.77
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$9.65
Resistance Level
$10.46
Current Trend
Strong Downtrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.38
Wall Street Target
$12.09
(+20.9%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-3.8% cheaper
PE vs Historical
16.4 vs 18.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.8%
(market-implied from PE analysis)
1-Year Target
$9.62
(-4%)
2-Year Target
$9.25
(-8%)
3-Year Target
$8.90
(-11%)
3-Yr Target (if PE normalizes)
(PE: 16→18)
$10.00
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.2%)
$18.26
(+83%)
Base:
(SPY PE: 16.4, Growth: 10.2%)
$13.38
(+34%)
Bear:
(PE: 13.9, Growth: 10.2%)
$11.37
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.55 | Current EPS (TTM): $0.49
Bull Case
$13.76
(+39%)
Analyst growth 24.2%, PE expands to 22.6
Base Case
$12.51
(+26%)
Market implied 24.2%, PE stable at 20.6
Bear Case
$6.85
(-31%)
Severe decline -20.0%, PE contracts to 17.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.4 to 18.4
Stabilization Target:
$11.24
(+12.4%)
PE Expansion Potential:
+12.4%
Share & Embed Analysis
Last updated: March 31, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM
Data refreshes hourly during market hours. Next update: 1:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
